Navigation Links
NOVA(R) Renal: A Safe Alternative to Contrast Enhanced MRA/MRI
Date:6/3/2008

Breakthrough Technology Avoids Use of Risky Gadolinium Injections

CHICAGO, June 3 /PRNewswire/ -- VasSol's introduction of NOVA(R) Renal, a gadolinium-free procedure, offers a safe alternative to the standard contrast-enhanced Magnetic Resonance Angiography (MRA) and Magnetic Resonance Imaging (MRI) scans for patients suffering from renal disease. Contrast enhanced renal MRA/MRI has traditionally required the injection of a gadolinium based agent which the FDA has linked to the occurrence of a potentially life-threatening disease, Nephrogenic Systemic Fibrosis (NSF). NOVA(R) Renal provides a comprehensive evaluation of the renal arteries without contrast or ionizing radiation.

Who's at Risk?

According to a report by the Centers for Disease Control (CDC), one in six individuals have kidney disease, threatening their renal function and putting them at greater risk when receiving a gadolinium-enhanced MRI scan.

About NOVA(R)

NOVA(R) is the first commercially available technology to measure actual blood flow rates in individual vessels using MRA/MRI scanners. The technology provides 3-D visualization of blood vessels, as well as quantitative blood flow measurements. NOVA(R) adds a new element to the traditional MRA/MRI scan by merging hemodynamic assessment with anatomic images. Non-invasive blood flow measurements with NOVA(R) provide clinicians with more information for the diagnosis and treatment of vascular disease.

About VasSol

VasSol, is founded on 12 years of multidisciplinary research and clinical work conducted at the University of Illinois at Chicago. Bringing together experts in the fields of circulatory fluid dynamics and computer modeling, VasSol developed NOVA(R), a vascular analysis technology, which helps answer the fundamental questions healthcare professionals confront when treating vascular disease: what is the severity, how is the condition best treated and what is the outcome? The VasSol missi
'/>"/>

SOURCE VasSol
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Advanced Instruments Anoxomat Mark II Anaerobic System is Excellent Alternative to Anaerobic Chambers, Gas Bags in Clinical Laboratories
2. Flat carbonated drinks not an effective alternative to oral rehydration solution
3. Saline is Safe Alternative to Harmful Cough and Cold Products
4. Eastern Remedies: Alternative Treatment for the U.S. Healthcare System
5. Natural Alternatives International, Inc. Announces Third Quarter Results
6. Telemedicine a Cost-Effective Alternative to ER Visits
7. An Alternative to Medicinal Marijuana
8. An Alternative to Surgery for Treating Skin Cancer
9. Send Me An Angel(TM) Pairs Senior Citizens With Their Peers in Alternative Care
10. SAPPHIRE trial shows long-term benefit of carotid stenting as alternative to surgery
11. Angioplasty Proves Reasonable Alternative to Bypass Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 2Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 3Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 4Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 5Health News:Regenerus Life Enhancement Programme from The Diagnostic Clinic Will Take the Fear Out of Ageing 6Health News:Wellness Manufacturer Wins Two 2009 American Spa Awards 2Health News:NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus 2Health News:Americans United for Life Action Fights the Abortion Bailout by Supporting the Nelson-Hatch-Casey Amendment 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3
Breaking Medicine Technology:CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 1DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 2DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 3DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 4DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 5DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 6DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 7DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 8DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 9DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 10DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 11DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 12DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results 54154 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 1Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 2Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 3Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 4Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 5Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 6Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 7Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 8Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 9Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 10Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 11Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 12Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 13Cornerstone Therapeutics Reports Second Quarter and First Half 2009 Financial Results 54150 14Dr James OConnell Named J H Kanter Prize Laureate 54148 1Dr James OConnell Named J H Kanter Prize Laureate 54148 2Dr James OConnell Named J H Kanter Prize Laureate 54148 3